9.13
Amicus Therapeutics Inc Stock (FOLD) Latest News
Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - GlobeNewswire
HealthInvest Partners AB Has $3.08 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Transcend Capital Advisors LLC - MarketBeat
Wells Fargo & Company Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to Hold at StockNews.com - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary - Benzinga
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance
Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes - TipRanks
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates - MSN
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net
Amicus Therapeutics Inc FOLD - Stockhouse Publishing
BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating - Investing.com Canada
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Milton Daily Standard
AMICUS THERAPEUTICS Earnings Results: $FOLD Reports Quarterly Earnings - Nasdaq
Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30% - Nasdaq
Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise -February 19, 2025 at 07:34 am EST - Marketscreener.com
Amicus Therapeutics Reports Strong 2024 Financial Results and Positive Outlook for 2025 - TradingView
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewswire
BRIEF-Amicus Therapeutics Q4 Net Income USD 14.7 Million - TradingView
Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Nigeria
Amicus Therapeutics FY 2024 Earnings Preview - MSN
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):